



First Quarter 2024 Financial Results & Business Update

May 8, 2024

On Today's Call

• Welcome

Elhan Webb, CFA, Senior Vice President, Investor Relations

• Overview

Richard Paulson, President and Chief Executive Officer

Pipeline Update

Dr. Reshma Rangwala, Chief Medical Officer and Head of Research

Commercial Highlights
 Scheme Charge Chief Commercial

Sohanya Cheng, Chief Commercial Officer

- Financial Results and Guidance Michael Mason, *Chief Financial Officer*
- Closing Remarks Richard Paulson, President and Chief Executive Officer
- Q&A Session

Forward-looking Statements and Other Important Information

This presentation contains forward-looking statements within the meaning of The Private Securities Litigation Reform Act of 1995. Such forward-looking statements include those regarding the anticipated benefits of and activities under the refinancing transactions, expectations for our use of proceeds from the Secured Term Loan, the expected closing date for the exchange transactions and the Company's ability to complete the exchange transactions; Karyopharm's guidance on its 2024 total revenue, 2024 U.S. net product revenue and 2024 R&D and SG&A expenses; Karyopharm's expected cash runway; beliefs about the market opportunity and annual peak revenue opportunities for selinexor; the ability of selinexor to treat patients with multiple myeloma, endometrial cancer, myelofibrosis, diffuse large B-cell lymphoma, and other diseases; expectations related to future clinical development and potential regulatory submissions of selinexor; expectations with respect to commercialization efforts; submissions to, and the review and potential approval of selinexor or any of its other product candidates by, regulatory authorities, including the Company's regulatory strategy, the anticipated availability of data to support such submissions, timing of such submissions and actions by regulatory authorities and the potential availability of accelerated approval pathways; the expected design of the Company's clinical trials; and the therapeutic potential of and potential clinical development plans for Karyopharm's product candidates, especially selinexor. Such statements are subject to numerous important factors, risks and uncertainties, many of which are beyond Karyopharm's control, that may cause actual events or results to differ materially from Karyopharm's current expectations. For example, there can be no guarantee that Karyopharm will successfully commercialize XPOVIO or that any of Karyopharm's drug candidates, including selinexor, will successfully complete necessary clinical development phases or that development of any of Karyopharm's drug candidates will continue. Further, there can be no guarantee that any positive developments in the development or commercialization of Karyopharm's drug candidate portfolio will result in stock price appreciation. Management's expectations and, therefore, any forward-looking statements in this press release could also be affected by risks and uncertainties relating to a number of other factors, including the following: the adoption of XPOVIO in the commercial marketplace, the timing and costs involved in commercializing XPOVIO or any of Karyopharm's drug candidates that receive regulatory approval; the ability to obtain and retain regulatory approval of XPOVIO or any of Karyopharm's drug candidates that receive regulatory approval; Karyopharm's results of clinical and preclinical trials, including subsequent analysis of existing data and new data received from ongoing and future trials; the content and timing of decisions made by the U.S. Food and Drug Administration and other regulatory authorities, investigational review boards at clinical trial sites and publication review bodies, including with respect to the need for additional clinical trials; the ability of Karyopharm or its third party collaborators or successors in interest to fully perform their respective obligations under the applicable agreement and the potential future financial implications of such agreement; Karyopharm's ability to enroll patients in its clinical trials; unplanned cash requirements and expenditures; development or regulatory approval of drug candidates by Karyopharm's competitors for products or product candidates in which Karyopharm is currently commercializing or developing; the direct or indirect impact of the COVID-19 pandemic or any future pandemic on Karyopharm's business, results of operations and financial condition; and Karyopharm's ability to obtain, maintain and enforce patent and other intellectual property protection for any of its products or product candidates. These and other risks are described under the caption "Risk Factors" in Karyopharm's Annual Report on Form 10-K for the year ended December 31, 2023, which was filed with the Securities and Exchange Commission (SEC) on February 29, 2024, and in other filings that Karyopharm may make with the SEC in the future. Any forward-looking statements contained in this presentation speak only as of the date hereof, and, except as required by law, Karyopharm expressly disclaims any obligation to update any forwardlooking statements, whether as a result of new information, future events or otherwise. Karyopharm regularly uses its website to post information regarding its business, drug development programs and governance. Karyopharm encourages investors to use www.karyopharm.com, particularly the information in the section entitled "Investors," as a source of information about Karyopharm. References to www.karyopharm.com in this presentation are not intended to, nor shall they be deemed to, incorporate information on www.karyopharm.com into this presentation by reference. Other than the currently approved indications of XPOVIO, selinexor is an investigational drug that has not been approved by the FDA or any other regulatory agency, and the safety and efficacy of this drugs has not been established by any agency.

XPOVIO[®] (selinexor) and NEXPOVIO[®] (selinexor) are registered trademarks of Karyopharm Therapeutics Inc. Any other trademarks referred to in this presentation are the property of their respective owners. All rights reserved.



Richard Paulson *Chief Executive Officer*

OVERVIEW



Driven to Positively Impact Lives and Defeat Cancer Through Scientific Innovation

Committed to Driving Value with Next Stage of Growth


Novel & Differentiated Mechanism of Action

Transformative Late-Stage Clinical Development Opportunities

Strong Financial Position to Deliver 3 Pivotal Studies

Global Commercial Presence & Approvals in over 40 Countries

Potential For ~\$2 Billion Annual Peak U.S. Revenues^{1,2}




internal estimates, including market research conducted for each indication.

1. Includes projected potential selinexor revenues in JAKi-naïve myelofibrosis, TP53 wild type endometrial cancer and multiple myeloma. 2. Annual U.S. peak revenue opportunity is not guidance, but instead represents what the Company believes to be Karyopharm's peak revenue opportunity based on

5 ©2024 KARYOPHARM THERAPEUTICS INC.

Debt Exchange Strengthens Opportunity to Realize Multiple Phase 3 Readouts in 2025; Collective \$2B+ Potential Annual Peak Revenue Opportunity^{1, 2}



* Multiple myeloma.

6 ©2024 KARYOPHARM THERAPEUTICS INC.

Includes projected potential selinexor revenues in: JAKi-naïve myelofibrosis, TP53 wild type endometrial cancer and multiple myeloma.
 Annual U.S. peak revenue opportunity is not guidance, but instead represents what the Company believes to be Karyopharm's peak revenue opportunity based on internal estimates, including market research conducted for each indication.
 Selinexor + pomalidomide + dexamethasone.



PIPELINE UPDATE




Focused High Potential Pipeline with 3 Pivotal Studies Across Cancers With High Unmet Needs

	Regimen	Indication	Study Name	Early Stage	Mid Stage	Late Stage	Commercial
	w/dexamethasone	Multiple myeloma (penta-refractory)	STORM				•
(selinexor)	w/bortezomib + dexamethasone	Multiple myeloma (2L+)	BOSTON				•
	monotherapy	DLBCL (R/R)	SADAL				•
SELINEXOR Pivotal Phase 3s	w/pomalidomide + dexamethasone	Multiple myeloma (2L+; post anti- CD38)	XPORT-MM-031 ^{1,2}				
	w/ruxolitinib	Myelofibrosis (treatment naïve)	SENTRY (XPORT-MF-034)				
	monotherapy	Endometrial cancer (maintenance; <i>TP53</i> wild-type)	XPORT-EC-042			•	
SELINEXOR Phase 2s	Monotherapy ³ (agreement with SOBI ⁴)	Myelofibrosis (treatment naïve)	SENTRY-2 (XPORT-MF-044)				
	w/mezigdomide ⁵ (clinical collaboration with BMS)	Multiple myeloma (relapsed/refractory)	STOMP		•		
	monotherapy	Endometrial cancer (maintenance)	SIENDO			•	
	w/R-GDP	DLBCL (R/R)	XPORT-DLBCL-0306			•	
ELTANEXOR	monotherapy	Myelodysplastic neoplasms (relapsed/refractory)	KPT-8602-801		•		
hematologic cancer solid tumor cancer							

1. EMN29 Study: Sponsored by European Myeloma Network. 2. Versus elotuzumab, pomalidomide, and dexamethasone. 3. With option to add JAK inhibitors. 4. For supply of pacritinib. 5. To be initiated as an arm in the STOMP trial. 6. XPORT-DLBCL-030 is a Phase 2/3.

ENDOMETRIAL CANCER


Potential for Significant Paradigm Shift for the Treatment of Women with Advanced or Recurrent *TP53* Wild-Type (WT) Endometrial Cancer (EC)



The safety and efficacy of selinexor in endometrial cancer has not been established and has not been approved by the U.S. FDA or any other regulatory authority for use in endometrial cancer.

 Mirza, M et al. (2023, October 20-24). Dostarlimab + Chemotherapy for the Treatment of Primary Advanced or Recurrent Endometrial Cancer: Analysis of Progression Free Survival and Overall Survival Outcomes by Molecular Classification in the ENGOT-EN6-NSGO/GOG-3031/RUBY Trial. [Conference presentation]. ESMO 2023 Congress, Madrid, Spain. 2. Clarivate/DRG Endometrial Carcinoma Epidemiology Dashboard (2022 figures, pub 2020) 3. Mutated p53 portends improvement in outcomes when bevacizumab is combined with chemotherapy in advanced/recurrent endometrial cancer: An NRG Oncology study, Leslie, Kimberly K. et al. Gynecologic Oncology, Volume 161, Issue 1, 113 – 121 3 Emerging Role of *TP53* and Importance of Molecular Profiling in the Evolving Landscape of Advanced and Recurrent Endometrial Cancer (A/R EC)

Patients Who are Both TP53 Wild-Type AND pMMR Represent 40-55% of all A/R EC^{2,3,4,5}



The safety and efficacy of selinexor in endometrial cancer has not been established and has not been approved by the U.S. FDA or any other regulatory authority.

Selinexor maintenance for patients with TP53wt advanced or recurrent endometrial cancer: Long-term follow up of efficacy and safety subgroup analysis of the ENGOT-EN5/GOG-3055/SIENDO Study⁶

GOG FOUNDATION*

Jalid Sehouli¹, Ignace Vergote, Erika Hamilton, Alejandro Pérez Fidalgo, Toon Van Gorp, Giovanni Scambia, Jaroslav Klat, Tally Levy, Stephen Welch, Debra L Richardson, Eva Maria Guerra Alia, Stéphanie Henry, Pauline Wimberger, David S. Miller, Jerónimo Martínez, Bradley J Monk, Pratheek Kalyanapu, Mansoor Raza Mirza, Vicky Makker


¹NOGGO and Department of Gynecology, European Competence Center for Ovarian Cancer, Charité Comprehensive Cancer Center, Charité–Berlin University of Medicine

congress.esgo.org

European Network of 👘 Symaecological Oncological Trial group

 Deficient mismatch repair. 2. Mirza, M et al. (2023, October 20-24). Dostarlimab + Chemotherapy for the Treatment of Primary Advanced or Recurrent Endometrial Cancer: Analysis of Progression Free Survival and Overall Survival Outcomes by Molecular Classification in the ENGOT-EN6-NSGO/GOG-3031/RUBY Trial. [Conference presentation]. ESMO 2023 Congress, Madrid , Spain. 3. Vergote I, et al. J Clin Oncol. 2023 Sep 5:JCO2202906.2023 Oral Selinexor as Maintenance Therapy After First-Line Chemotherapy for Advanced or Recurrent Endometrial Cancer, https://pubmed.ncbi.nlm.nih.gov/37669480/. 4. Slomovitz B et al. Presentation at American Society for Clinical Oncology Plenary Series; July 25, 2023. 5. Leslie KK, et al Gynecol Oncol. 2021 April ; 161(1): 113–121 6.Conference presentation ESGO 2024 Congress, Barcelona, Spain

Updated Data from SIENDO Study¹ Indicate Encouraging Signal of PFS Benefit with Median PFS > Two Years in *TP53* Wild-Type EC



Most common adverse events in *TP53* wt exploratory subgroup: nausea (90%, grade \geq 3: 12%), vomiting (60%, grade \geq 3: 3%), thrombocytopenia (42%, grade \geq 3: 10%) and diarrhea (42%, grade \geq 3: 4%). TEAE's leading to discontinuation 16% and death 0%.


The safety and efficacy of selinexor in endometrial cancer has not been established and has not been approved by the U.S. FDA or any other regulatory authority.

Data cut September 1, 2023

NR, not reached.

SIENDO Study: In the *TP53* WT Exploratory Subgroup, PFS Improvement Observed Regardless of MMR Status, Strongest Signal in *TP53* WT / pMMR

Long-Term Follow-Up¹: PFS in *TP53* WT Exploratory Subgroup Based on MMR status



Median follow-up: 31.6 months

Median follow-up: 27.3 months

Invited to Present Updated Data Cut and New Analysis at ASCO Plenary Series Rapid Abstract Updates Oral Session

The safety and efficacy of selinexor in endometrial cancer has not been established and has not been approved by the U.S. FDA or any other regulatory authority.

Data cut September 1, 2023 NR, not reached.

1. Presented at IGCS 2023 Annual Global Meeting and ESGO 2024 Congress

XPORT-EC-042* Global Phase 3, Randomized, Double-Blind Trial of Selinexor as Maintenance Therapy for Patients with *TP53* Wild-Type, Advanced or Recurrent Endometrial Cancer

Study is Actively Enrolling

TP53 Wild-Type Status is Assessed by Companion Diagnostic Partner Foundation Medicine¹

Study in Collaboration with ENGOT² and GOG³



The safety and efficacy of selinexor in endometrial cancer has not been established and has not been approved by the U.S. FDA or any other regulatory authority.

Top-line Data in 1H 2025

PFS, progression-free survival; PD, progressive disease; QW, every week

1. Utilizing Foundation Medicine's tissue-based comprehensive genomic profiling test to identify TP53 status 2.European Network for Gynaecological Oncological Trial groups 3. Gynecologic Oncology (GOG) Foundation

MYELOFIBROSIS



Selinexor Has the Potential to Define a New Treatment Paradigm in MF*

Treatment Landscape and Unmet Need

Population living with MF:

• ~20,000 in the $U.S^{1;}$ ~17,000 in EU^{1}

No other approved class of therapy other than JAK inhibitors

 Ruxolitinib generates over \$1 billion² revenues annually in MF in the U.S.

Significant unmet need in 1L treatment with current standard of care, ruxolitinib

- Only ~35% of patients achieve SVR35 with ruxolitinib³
- <50% achieve TSS50³

Selinexor

- XPO1 inhibition is a novel and potentially fundamental mechanism in MF
- Synergism with ruxolitinib observed in preclinical data⁴
- Rapid, deep and sustained spleen response, robust symptom improvement and rapid, sustained cytokine reduction across all subgroups*
- Potentially disease modifying with rapid normalization of platelets, maintenance of hemoglobin levels and rapid cytokine reduction
- Generally tolerable and manageable side effect profile enabling sustained therapy

* Based on selinexor+ruxolitinib Ph 1 results, n=14; using data cut as of August 1, 2023

The safety and efficacy of selinexor in myelofibrosis has not been established and has not been approved by the U.S. FDA or any other regulatory authority for use in myelofibrosis.

SVR 35: Spleen volume reduction ≥ 35%; TSS50: Total symptom score reduction of ≥50%

1. Mehta et.al. Leuk Lyphoma 2014 Mar ;55(3):595-600 and US Census data; Clarivate/DRG Epidemiology Data (2022 figures, pub 2019) 2. Incyte Q4 2023 Results 3. MANIFEST and TRANSFORM Phase 3 studies, ASH 2023 4. Al-Ali, et al. Hematologica. 2016;101(9):1065

Rapid and Deep SVR35 Achieved with Selinexor 60 mg + Ruxolitinib in Ph1 Trial

		SVR35		
		Selinexor 60mg +ruxolitinib		
Population	Timepoint	n/N (%)		
Efficacy	Week 12	10/12 ¹ (83.3)		
Evaluable	Week 24	11/12 (91.7)		
Intent to Treat	Week 12	10/14 (71.4)		
Intent-to-Treat	Week 24	11/14 (78.6)		


SVR35, spleen reduction volume ≥35%

The most common adverse events were GI side effects:


• Nausea (79%, grade ≥3: 7%), anemia (64%, grade ≥3: 43%), thrombocytopenia (64%, grade ≥3: 29%), and fatigue (57%, grade ≥3: 0%)

The safety and efficacy of selinexor in myelofibrosis has not been established and has not been approved by the U.S. FDA or any other regulatory authority for use in myelofibrosis.

-60



1. Two patients discontinued prior to Week 24 2. n=12; one patient discontinued prior to week 12; one patient with missing data at week 12 who subsequently discontinued prior to week 24 50% of All Patients Treated with Selinexor 60 mg + Ruxolitinib Achieved SVR35 and TSS50 at Week 24; 75% of Patients Achieved Both at Anytime



* 2 patients with no baseline symptoms (TSS = 0) were excluded from the TSS50 response and the SVR35/TSS50 dual response analyses.

The safety and efficacy of selinexor in myelofibrosis has not been established and has not been approved by the U.S. FDA or any other regulatory authority for use in myelofibrosis.

Meaningful Improvement Observed in TSS50 and Absolute TSS with Selinexor 60 mg + Ruxolitinib at Week 24

		TSS50 ¹	
Population	Timepoint	Selinexor 60mg +ruxolitinib n/N (%)	
Efficacy	Week 12	8/10 ³ (80.0)	
Evaluable	Week 24	7/9 ⁴ (77.8)	
Intent to Treat	Week 12	8/12 (66.7)	
Intent-to-Treat	Week 24	7/12 (58.3)	

	Absolute TSS ²
Timepoint	Selinexor 60mg +ruxolitinib mean (SD*)
Baseline	27.3 (17.43)
Week 24	-18.5 (13.48)


* standard deviation

The safety and efficacy of selinexor in myelofibrosis has not been established and has not been approved by the U.S. FDA or any other regulatory authority for use in myelofibrosis.

Data cut August 1, 2023	1. Proportion of patients with ≥50% reduction in TSS from baseline to Week 24 based on modified MPN-SAF TSS V.4.0 2. Average reduction in total symptom score at week 24 relative to baseline, calculated for each evaluable subject. Least square mean of the absolute
19 ©2024 KARYOPHARM THERAPEUTICS INC.	TSS change was not estimated in the ITT population due to limitations in sample size 3. One patient discontinued prior to week 12; one patient with missing data at week 12, who subsequently discontinued prior to week 24 4. Two patients discontinued prior to Week 24 and one had missing data

Efficacy Observed with Selinexor in Combination with Suboptimal Dose of Ruxolitinib (<5 mg^{*}) Further Supports XPO1 as a Fundamental MoA in MF

Retrospective, Exploratory Analysis from Phase 1 Selinexor (60 mg) + Ruxolitinib Study (034)



Spleen Volume Reduction

*Patients received ruxolitinib at \leq 5 mg BID for at least five out of the first six cycles


"Based on limited clinical data, long-term maintenance at a 5 mg twice daily dose has not shown responses and continued use at this dose should be limited to patients in whom the benefits outweigh the potential risks." Jakafi (ruxolitinib) U.S. Package Insert, January 2023

The safety and efficacy of selinexor in myelofibrosis has not been established and has not been approved by the U.S. FDA or any other regulatory authority. Data cut August 1, 2023 1. One patient with missing TSS50 score

BID: Twice daily; MoA: Mechanism of Action; MF: Myelofibrosis

Total Symptom Score Reduction¹

Initiated SENTRY-2 (XPORT-MF-044^{*}) Phase 2 Trial Evaluating Selinexor As Monotherapy in JAKi Naïve MF Patients with Lower Platelet Counts



Add momelotinib³ if plt >50 x10⁹/L hemoglobin level is <10 g/dL


agreement with SOBI

1. Evaluated in the myelofibrosis assessment form (MFSAF) 2. Ruxolitinib dose based on platelet count per prescribing information 3.In the U.S. only 4. For supply of pacritinib

Plt: platelet; QW: Once weekly; SVR 35: Spleen volume reduction ≥ 35%; TSS50: Total symptom score reduction of ≥50%; PD: pharmacodynamic; PK: Pharmacokinetic

SENTRY (XPORT-MF-034^{*}) Phase 3 Trial Evaluating Selinexor in Combination with Ruxolitinib in Treatment-naïve Myelofibrosis

Study is Actively Enrolling



Randomization stratified by:

- Dynamic International Prognostic Scoring System (DIPSS) risk category intermediate -1 vs. intermediate -2 or high-risk
- Spleen volume <1800 cm³ vs. >1800 cm³ by MRI/CT scan
- Baseline platelet counts 100-200 x 10⁹/L vs. >200 x 10⁹/L

Top-line Data Expected in 2H 2025

1. Ruxolitinib dose based on platelet count per prescribing information 2. Evaluated in the myelofibrosis assessment form (MFSAF)


BID: Twice daily; Plt: Platelet; QW: Once weekly; SVR 35: Spleen volume reduction ≥ 35%; TSS50: Total symptom score reduction of ≥50%

MULTIPLE MYELOMA






Generating Evidence on the Role and Effectiveness of Selinexor pre and post T-cell Mediated Therapies



Phase 3 Global Study (XPORT-MM-031/ EMN29*) Evaluating SPd in Patients with Previously Treated Multiple Myeloma

Study is Actively Enrolling



The safety and efficacy of SPd has not been established and has not been approved by the FDA or any other regulatory authority

Top-line Data in 1H 2025

PI: proteasome inhibitor; mAB: monoclonal antibody


1. 40 mg selinexor dose was based upon evaluation of the safety and benefit of selinexor 40 and 60 mg doses in combo with Pd observed in the STOMP and 028 studies

Sohanya Cheng *Chief Commercial Officer*

COMMERCIAL HIGHLIGHTS



XPOVIO Net Product Revenue




1Q 2024 Highlights

- XPOVIO 1Q 24 net product revenue of \$26.0M, -8% YoY and +4% QoQ, amidst increased competition
- QoQ growth in new patient starts
 - Softness in refills following lower NRx in 4Q 23
 - Higher GTN in 1Q 24, typical for first quarter of the year
- Community setting accounted for 60% of XPOVIO net revenue in 1Q 24 driven by strong NRx growth and offset by refill impact
- Academic setting XPOVIO demand grew QoQ, with increased use immediately preceding and following T cell therapies in later lines
- XPOVIO new patient mix in 2-4L stable QoQ
- Re-affirming full year 2024 XPOVIO net product revenue guidance of \$100-\$120M

Selinexor Approved in Over 40 Countries with Reimbursement Achieved in Key Global Markets

- Positive recommendation from NICE to expand reimbursement of NEXPOVIO in the UK for 2L+ MM in April 2024
- XPOVIO added to China's National Reimbursement Drug List (NRDL), effective as of January 1, 2024
- Reimbursement approval for NEXPOVIO in Germany in December 2023



FINANCIAL HIGHLIGHTS AND MILESTONES

TOPP

Recent Transactions Extend Maturities into 2028 and 2029

Convertible Notes Exchange	 Extends maturity on 86% of convertible debt to 2029 Exchanges \$148.0 million of the current \$172.5 million 3% Convertible Notes due 2025 at a 25% discount to par in exchange for \$111.0 million newly issued 6% Second Lien Convertible Notes due in 2029 plus warrants; Issued \$5.0 million New Convertible Notes to HCRx Remaining \$24.5 million of existing convertible notes due October 2025 	\$69.2 \$172.5 2024-2026 • Minimum payments to HCRx through September 2026
New Secured	 New \$100.0 million Senior Secured Term Loan due 2028 provided by the top four existing convertible note holders and HCPx 	Convertible Notes due October 2025 Post-Transactions
Term Loan	existing convertible note holders and HCRx	\$116
Amended HealthCare Royalty (HCRx) Agreement	 \$69.2 million of the proceeds from the new Senior Secured Term Loan used to address the remaining principal portion of HCRx's \$135.0 million investment Eliminates potential gross-up payments to HCRx Reduces royalty rate on worldwide XPOVIO net revenues and future products to 7.0% down from 12.5% 	\$24.5\$10020252028-2029New Convertible Notes due 2029New Senior Secured Term LoanExisting Convertible Notes due October 2025

Maturity Profile

Pre-Transactions

1Q 2024 Financial Results

Statements of Operations (\$ millions)	1Q 2024	1Q 2023
Total Revenue	\$33.1	\$38.7
XPOVIO Net Sales	26.0	28.3
License and Other Revenue	7.1	10.4
Total Operating Expenses	\$66.8	\$69.6
Cost of Sales	1.9	1.4
Research and Development Expenses	35.4	32.3
Selling, General & Administrative Expenses	29.5	35.9
Net Loss	\$37.4	\$34.1
Net Loss per share	\$0.32	\$0.30

Balance Sheet (\$ millions)	March 31, 2024	Dec 31, 2023
Cash, Cash Equivalents Restricted Cash and Investments	\$149.3	\$192.4

2024 Financial Guidance

- Total Revenue of \$140-\$160
 million
- U.S. XPOVIO Net Product
 Revenue of \$100-\$120 million
- R&D and SG&A Expenses of \$260-\$280 million, including estimated non-cash stock compensation of ~ \$20-\$25 million
- Cash runway expected to be sufficient to fund planned operations into the end of 2025*




Richard Paulson *Chief Executive Officer*

CLOSING REMARKS



Accelerating Innovation and Growth Strategy with Key Milestones in 2024 and 2025



Myelofibrosis

- Report updated results from the Phase 1 trial of selinexor + ruxolitinib in treatment-naïve MF (2024)
- Report preliminary data from MF-044 Phase 2 study with single agent selinexor in JAKi naïve MF with platelet counts below 50 × 10⁹/L. (2H 2024)
- Report top-line results from Phase 3 trial of selinexor + ruxolitinib in treatment-naïve MF (2H 2025)






APPENDIX

SIENDO*: A Randomized Double-Blind, Phase 3 Trial of Maintenance with Selinexor / Placebo after Combination Chemotherapy for Patients with Advanced or Recurrent Endometrial Cancer^{1,2}

Enrollment Completed



The safety and efficacy of selinexor in endometrial cancer has not been established and has not been approved by the U.S. FDA or any other regulatory authority.

BICR, blinded independent central review; CR, complete response; EDM, exonuclease domain mutation; IHC, immunohistochemistry; MSI, microsatellite instability; OS, over survival; PFS, progression-free survival; PO, per oral; POLE, polymerase epsilon; PR, partial response; QW, once weekly; R, randomized; RECIST, response evaluation criteria solid tumors; TP53, tumor protein 53 ge

35 ©2024 KARYOPHARM THERAPEUTICS INC.

1. Maintenance With Selinexor/Placebo After Combination Chemotherapy in Participants With Endometrial Cancer [SIENDO] (ENGOT-EN5).Updated May 30, 2023. Accessed June 26, 2023. https://www.clinicaltrials.gov/study/NCT03555422?term=NCT03555422 2. Vergote I, et al. Presentation at: European Society for Clinical Oncology Virtual Plenary March 17-18, 2022. Abstract VP2-2022